Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain officers for alleged violations of federal securities laws during the Class Period from July 25, 2024, to October 22, 2025 [1][2]. Summary by Sections Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Integer securities during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's business and operations [3]. Allegations Against Integer - Integer allegedly overstated its competitive position in the expanding EP manufacturing market [8]. - Despite claims of strong visibility into customer demand, the Company was reportedly experiencing a decline in sales related to two of its EP devices [8]. - Integer mischaracterized its EP devices as a long-term growth driver for its C&V segment [8]. - Consequently, the positive statements made by Defendants regarding the Company's business and prospects were deemed materially false and misleading [8]. Investor Information - Investors who suffered losses in Integer have until February 9, 2026, to request appointment as lead plaintiff [3]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if successful [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [5]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

NEW YORK--(BUSINESS WIRE)---- $ITGR #BFA--Integer Holdings Corporation Lowered Sales Outlook Triggers Securities Fraud Class Action after Stock Drops Over 32% -- Investors Urged to Contact BFA. ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Integer Holdings Corporation ("Integer†or the "Company†) (NYSE: ITGR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON INTEGER (ITGR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On October 2. ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) securities between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants failed to disclose that: (i) the Co ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation and certain executives, alleging misleading statements and failure to disclose adverse facts about the company's business and operations during the class period from July 25, 2024, to October 22, 2025 [1] Company Overview - Integer Holdings Corporation, based in Plano, Texas, is one of the largest medical device contract development and manufacturing organizations globally, focusing on cardiac rhythm management and cardiovascular medical devices [2] - Approximately 60% of Integer's total revenue is generated from its cardiovascular product line, which includes electrophysiology devices that diagnose and map the heart's electrical activity [2] Industry Context - Prior to the class period, the electrophysiology device market experienced a technological revolution with the development of pulse field ablation procedures, which treat atrial fibrillation [3] - The integration of electrophysiology devices and pulse field ablation platforms became a significant growth driver for Integer's cardiovascular segment [3] Allegations in the Class Action - The lawsuit claims that during the class period, Integer's executives made materially false and misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [4] - Specific allegations include: 1. Integer overstated its competitive position in the EP manufacturing market 2. The company experienced a deterioration in sales for two of its EP devices, contrary to claims of strong customer demand 3. Integer mischaracterized its EP devices as a long-term growth driver for its cardiovascular segment [4] Disclosure of Financial Performance - On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which was below analysts' expectations [5] - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, with expectations of declining sales for three new products, including two electrophysiology products [5] - Following this disclosure, Integer's stock price fell by $35.22, or over 32%, from $109.11 to $73.89 per share [5]

Question-and-Answer SessionI want to start off big picture. You've had a CEO transition recently, you did notice, I know. But I'd love if you could just sort of step back and talk about what you see coming in. Some might call it a rocky start, you might call it an opportunity, but I'm going to leave that for you to label.Payman KhalesCEO, President & Director Yes. Thank you for that, and thanks for having us. It's great to be here. I certainly see this as an opportunity, and I'm very bullish about our busin ...

Financial Data and Key Metrics Changes - The core business is expected to grow between 4%-7%, which aligns with the weighted average market growth rate of 4%-6% [6][8] - The company anticipates a short-term headwind due to three specific products that are not achieving the expected market adoption in 2026, impacting growth [7][15] - The stock is considered undervalued by management, with a $200 million share repurchase program authorized to reflect confidence in the company's fundamentals and growth strategy [11][23] Business Line Data and Key Metrics Changes - The company focuses on fast-growing markets such as electrophysiology, neurovascular, structural heart, and neuromodulation, with 80% of the product development sales pipeline concentrated in these areas [4][5] - Despite headwinds from specific products, the overall portfolio is still expected to grow at market rates, with double-digit growth in other segments [28][29] Market Data and Key Metrics Changes - The electrophysiology market has been performing well, with significant growth driven by new technologies [25][26] - The company has a diversified portfolio, which mitigates risks associated with individual product performance, as no single program represents a significant portion of total revenues [17][19] Company Strategy and Development Direction - The company aims to be the most innovative contract development and manufacturing organization (CDMO) in the world, focusing on building critical engineering and manufacturing capabilities [10][11] - The strategy includes targeted acquisitions to enhance capabilities and a strong emphasis on early engagement with customers during product development cycles [4][5] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term event, expecting to return to growth in the second half of 2026 and above-market growth in 2027 [8][23] - The company is committed to maintaining operational efficiencies and managing costs during the anticipated air pocket period [39][40] Other Important Information - The company has a global manufacturing footprint, which is seen as a competitive advantage in managing potential tariff impacts [47][50] - There is a strong focus on integrating artificial intelligence into manufacturing processes to enhance efficiency and data utilization [58][59] Q&A Session Summary Question: What will the company do differently with the new CEO? - The new CEO aims to build on the strong foundation and focus on delivering value through understanding customer needs and enhancing engineering capabilities [9][10] Question: What are the checks and balances to ensure revenue consistency? - The company relies on stable forecasts from customers for core products, while new products may have more variable adoption rates [19][20] Question: How does the company plan to manage expenses during the air pocket? - The company will focus on generating gross margin expansion through lean manufacturing and will be disciplined in managing fixed costs [39][40] Question: What is the expected impact of new product launches? - New product launches are expected to contribute to growth in the second half of 2026 and into 2027, with many products in development for several years [43][46] Question: How does the company view its global manufacturing strategy? - The global manufacturing strategy is based on expertise availability and cost competitiveness, allowing the company to mitigate tariff impacts effectively [47][50]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4%-7%, which aligns with the weighted average market growth rate of 4%-6% [6][8] - The company anticipates a short-term headwind due to three specific products not achieving the expected market adoption rate in 2026, impacting overall performance [7][15] - The stock is considered undervalued, with the fundamentals and core business remaining strong despite the current challenges [23][51] Business Line Data and Key Metrics Changes - The company focuses on fast-growing markets such as electrophysiology, neurovascular, structural heart, and neuromodulation, with 80% of the product development sales pipeline concentrated in these areas [4][5] - The electrophysiology portfolio has performed well over the past four to five years, although two specific products are facing adoption challenges [25][15] - The overall portfolio, excluding the impacted products, is still expected to grow at a strong double-digit rate [28] Market Data and Key Metrics Changes - The medical device market is experiencing significant innovation, particularly in electrophysiology and structural heart segments, which are expected to drive future growth [25][29] - The company has a global manufacturing footprint, which allows it to remain competitive despite potential tariff impacts [50][51] Company Strategy and Development Direction - The company aims to be the most innovative Contract Development and Manufacturing Organization (CDMO) in the world, focusing on building critical engineering and manufacturing capabilities [10][11] - The strategy includes targeted acquisitions to enhance capabilities and a strong emphasis on organic growth through innovative product launches [4][55] - The company is committed to maintaining operational efficiency through its Integer Production System, which focuses on lean manufacturing practices [39][40] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting to return to growth in the second half of 2026 and above-market growth in 2027 [8][61] - The company is confident in its strong pipeline and the ability to weather the current market pressures due to its diversified portfolio [17][63] - Management emphasizes the importance of customer relationships and market feedback in navigating product performance and demand [21][22] Other Important Information - A $200 million share repurchase program has been authorized, reflecting the board's confidence in the company's fundamentals and growth strategy [11][12] - The company has not previously engaged in share repurchase programs, indicating a strategic shift in capital allocation [12] Q&A Session Summary Question: What are the expectations for the company's growth in the coming years? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong core business [60][61] Question: How does the company plan to manage costs during the current air pocket? - The company will focus on generating gross margin expansion through lean manufacturing and will be disciplined in managing fixed costs during this period [39][40] Question: What is the company's approach to acquisitions? - The company is focused on tuck-in acquisitions that enhance critical capabilities rather than transformative acquisitions, which were more common in the past [55]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4% to 7% in 2026, which aligns with the weighted average market growth rate of 4% to 6% [6] - The company anticipates a short-term headwind due to three specific products that are not achieving the expected market adoption rates in 2026, impacting growth [6][7] - The stock is considered undervalued by management, reflecting strong fundamentals and financial strength [10][20] Business Line Data and Key Metrics Changes - The product development sales pipeline is approximately 80% focused on the fastest-growing markets, indicating a strong growth trajectory [5] - The electrophysiology portfolio has been performing well, with significant growth over the past four to five years, despite current headwinds [22][25] - The company is diversifying its portfolio, with no single program representing more than a few percentage points of total revenues, which mitigates risk [15] Market Data and Key Metrics Changes - The medical device market is experiencing a phase of multiple new product iterations, indicating a dynamic environment for innovation [21] - The company is well-positioned in the medtech ecosystem, partnering with both large and emerging companies [3] Company Strategy and Development Direction - The strategy focuses on building differentiated capabilities through organic growth and targeted acquisitions to enhance product offerings [4] - The company aims to be the most innovative contract development and manufacturing organization (CDMO) in the world, emphasizing engineering expertise and manufacturing efficiency [9][10] - Future growth is expected to be driven by new product launches in the second half of 2026 and into 2027, with a strong pipeline of innovative therapies [39][55] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting a return to growth in the second half of 2026 and above-market growth in 2027 [8][20] - The company is committed to maintaining operational efficiency and managing costs during this period, focusing on areas that will drive future growth [36] - Management is optimistic about the strength of the pipeline and the potential for market recovery, emphasizing the importance of execution and quality [9][20] Other Important Information - The company has initiated a $200 million share repurchase program, reflecting confidence in its financial strength and strategy [10] - The global manufacturing footprint is designed to mitigate risks associated with tariffs and ensure cost competitiveness [43][47] Q&A Session Summary Question: What is the outlook for the company's growth in 2026 and beyond? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong pipeline [55][56] Question: How does the company manage costs during the current air pocket? - The company plans to focus on manufacturing efficiencies and be disciplined in managing fixed costs during this period [36] Question: What is the company's strategy regarding acquisitions? - The company is focused on tuck-in acquisitions to build critical capabilities rather than transformative acquisitions [49]

Summary of Integer Holdings Corporation Conference Call Company Overview - Integer Holdings Corporation is one of the largest contract design, development, and manufacturing organizations in the medical device ecosystem, partnering with both large and emerging medical device companies [2][3] Core Markets and Strategy - The company focuses on four fast-growing markets: electrophysiology, neurovascular, structural heart, and neuromodulation [3] - Integer aims to build critical and differentiated capabilities in engineering, design, and manufacturing to increase participation in innovative therapies [3] - The development sales pipeline is projected to grow three times from 2017 levels by the end of 2023, with 80% of this pipeline directed towards the faster-growing markets [3][4] Financial Performance and Projections - Integer expects core business growth of 4-7% for 2026, slightly above the market growth rate of 4-6% [4] - The company anticipates headwinds from three specific new products, particularly impacting the first half of 2026, with expectations of recovery in the second half [4][5] - Preliminary guidance for 2026 indicates a potential decline of 2% to an increase of 2%, factoring in a 3-4% headwind from the underperforming products [15][20] Product Performance and Market Dynamics - The underperformance of three products is described as highly unusual, with expectations that this will not recur [5][8] - The company has a robust pipeline and anticipates returning to above-market performance in 2027 [5][42] - The electrophysiology (EP) business remains healthy despite the headwinds, with growth expected to continue in other areas of the EP market [27][28] Competitive Landscape - Integer is positioned to benefit from the growth in the EP market, including participation in various devices beyond just ablation [27][29] - The company views new entrants in the market as potential tailwinds, as overall market growth can lead to increased procedures and demand for their products [29] Future Growth Opportunities - Integer sees potential in renal denervation (RDN) but does not expect significant contributions in the immediate future [31][33] - The company has exposure to the left atrial appendage closure market, although it is a smaller part of their business [30] Operational Insights - Integer's gross margin strategy focuses on driving efficiencies through their Integer Production System and managing fixed costs [46][47] - The company has authorized a $200 million share repurchase program to enhance shareholder value while balancing organic investments and acquisitions [49] Customer Engagement and Development - Integer engages with customers early in the product development process, which strengthens partnerships and enhances their role as a critical supplier [24][25] - The company has 39 emerging customers for PMA products, with expectations for several to enter commercialization in the next couple of years [50] Conclusion - Integer Holdings Corporation is navigating short-term challenges due to specific product underperformance but maintains a strong outlook based on a robust pipeline and strategic market positioning. The company is focused on returning to above-market growth by 2027 while managing operational efficiencies and shareholder value initiatives [5][42][49]